Proximal Femur Locking Compression Plates Versus Trochanteric Nails
- Conditions
- Reverse Oblique Subtrochanteric FracturesReverse Oblique Intertrochanteric Fractures
- Interventions
- Device: Proximal femur locking plateDevice: Intertrochanteric nail
- Registration Number
- NCT01128868
- Lead Sponsor
- AO Clinical Investigation and Publishing Documentation
- Brief Summary
The purpose of this study is to compare the abductor muscle strength measured with a dynamometer in patients with reverse oblique inter- or subtrochanteric fractures treated either with a proximal femur locking plate or a trochanteric nail.
"Proximal femur locking plates" stands for both the PF-LCP (Synthes) and the PeriLoc (Smith \& Nephew). Trochanteric nails allowed in this study are the Proximal Femoral Nail Antirotation (PFNA), the Titanium Trochanteric Fixation Nail (TFN) and the Gamma Nail (GN).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
- Age ≥ 18 years
- Patients with closed or type 1 open reverse oblique intertrochanteric fractures (AO 31 - A3) or subtrochanteric fractures (transverse fracture line, main fracture line maximum 5 cm distal from the lesser trochanter; proximal extension of fracture allowed)
- Definitive fracture fixation with either a proximal femur locking plate or an intertrochanteric nail within 4 days after accident
- Signed written informed consent (by the subject or legal guardian) and agreement to attend the planned FUs
- Able to understand and read country national language at an elementary level
- Pathologic fracture
- Polytrauma
- Any displacement of a femoral neck fracture
- Additional fracture of one of the lower extremities that significantly affects the functional outcome
- Additional injury of the lower limb that significantly affects the functional outcome
- Fractures of the upper extremity if it affects the mobility of the patient
- Type 2 or 3 open fracture
- Drug or alcohol abuse
- Active malignancy
- ASA class V and VI
- Inability to walk independently prior to injury
- Neurological and psychiatric disorders that would preclude reliable assessment
- Patient is not able to come to the regular FUs
- Patients who have participated in any other device or drug related clinical trial within the previous month
- Pregnancy (tested with a urine pregnancy test) or women planning to conceive within the study period
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Proximal femur locking plate Proximal femur locking plate Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc) Trochanteric nail Intertrochanteric nail Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
- Primary Outcome Measures
Name Time Method Compare the functional outcome and abductor muscle strength measured with Lafayette Manual Muscle Tester in patients with reverse oblique inter- or subtrochanteric fractures treated either with a proximal femur locking plate or a trochanteric nail. one year As hip abductors are the most important muscles around the hip joint, the primary outcome parameter will involve objectively measuring hip abductor strength. Muscle strength will be assessed with a portable handheld dynamometer (Model 01163, Lafayette Instrument Company, Lafayette, IN, USA).
- Secondary Outcome Measures
Name Time Method Pain scores on the Visual Analog Scale one year Pain will be measured with the Visual Analogue Scale (VAS) (additionally assessed in a subgroup with the Brief Pain Inventory \[BPI\]).
Surgical details Initial hospitalization Skin-to-skin time, Fluoroscopy time, Blood loss, Blood transfusions, Surgeons experience.
Exploration of prognostic factors for the occurrence of complications, using the Fracture Risk Assessment Tool (FRAX) Initial hospitalization Fracture risk prior to injury will be calculated with the Fracture Risk Assessment Tool \[FRAX\] (http://www.shef.ac.uk/FRAX/index.htm).
Additionally, the fracture risk will be considered as a prognostic factor (in the absence of regular BMD measurements) for the analysis of complications.Patient outcome one year Patient outcome will be measured using the following outcome measurements:
Mobility measured with the "timed up \& go"-test (TUG), Lower Extremity Measure (LEM) for functional outcome, Length of hospital stay, Walking ability (Parker Mobility Score), Capacity to return to pre-residential status, Quality of life (Short Form-36 \[SF-36\]), Mortality.Local complications one year Local complication will be recorded and categorized:
Implant / surgery complications, Bone / fracture complications, Soft tissue / wound complications.Patient satisfaction with the Visual Analogue Scale one year Satisfaction measured with the VAS
Abductor muscle function with the Trendelenburg sign analysis one year Abductor muscle function test
Quality of reduction one year The results of fracture reduction are assessed with the following clinical and radiological evaluations : Varus/valgus deformity, Endo-/exorotation deformity, Limb length.
Revision rate one year Surgical revision includes all secondary surgical interventions that are related to the injury itself or the primary intervention. It is distinguished from planned revisions due to the injury (eg, planned soft tissue procedure) and revisions due to a complication. Revisions due to a complication are undertaken to resolve the problem and will therefore be documented in the complication form.
Systemic or general complications one year All complications affecting other regions of the body will be documented and evaluated as general/systemic complications, eg, thromboembolic complications, sepsis and others.
Trial Locations
- Locations (3)
Cantonal Hospital Chur
🇨🇭Chur, Switzerland
Cantonal Hospital Lucerne
🇨🇭Lucerne, Switzerland
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia